Evidence map›Paper›PMID 39171823›Full record

ArticlePathology international2024

Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms.

Masafumi Seki, Akira Satou, Renji Funato, Tomoko Tamaki, Naoki Wada, Norihiro Nakada, Hirofumi Matsumoto, Iwao Nakazato, Eriko Wada, Kaneko Sakurai and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Masafumi SekiDepartment of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Akira SatouDepartment of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.ORCID http://orcid.org/0000-0002-7921-6087
Renji FunatoDepartment of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Tomoko TamakiDepartment of Diagnostic Pathology, University of the Ryukyus Hospital, Okinawa, Japan.
Naoki WadaDepartment of Diagnostic Pathology, University of the Ryukyus Hospital, Okinawa, Japan.
Norihiro NakadaDepartment of Pathology, Nakagami Hospital, Okinawa, Japan.
Hirofumi MatsumotoDepartment of Pathology, Nakagami Hospital, Okinawa, Japan.
Iwao NakazatoDepartment of Pathology, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.
Eriko WadaDepartment of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.
Kaneko SakuraiDepartment of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.
Toyonori TsuzukiDepartment of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.ORCID http://orcid.org/0000-0002-4855-4366
Kennosuke KarubeDepartment of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0002-1205-858X

Funding

Japan Society for the Promotion of Science 23H02693Takeda Pharmaceutical Company
6 · The paper itself

Abstract

The identification of CD30 expression by immunohistochemistry is essential for the treatment of lymphomas using an antibody-drug conjugate targeting CD30. However, no standardized protocol for CD30 staining has been available. In this study, we compared three common automated immunostaining platforms {Bond III (B III), Dako Omnis (DO) and Ventana BenchMark ULTRA (VBMU)}. A primary antibody for CD30, the Ber-H2 clone, was diluted 50- to 400-fold for B III and DO, and ready-to-use antibody was used for VBMU. An enhancement step using a linker was introduced in all protocols. First, several candidate dilutions were selected for each platform by staining six cases. These candidate conditions were then confirmed with 60 cases of various types of peripheral T-cell lymphomas (PTCLs). The concordance rates of CD30 expression among platforms differed depending on cutoff values and antibody dilutions, except for anaplastic large cell lymphoma. The concordance rates among three platforms in the evaluation of "positive" or "negative" were 100% and 97% when the cutoff values were 1% and 10% respectively, if using 400-diluted antibody in B III and 100-diluted antibody in DO. This study demonstrated the feasibility of equalizing CD30 staining of PTCLs among different platforms by adjusting protocols.

Indexed as

Biomarkers, TumorImmunohistochemistryKi-1 AntigenHumansLymphoma, T-Cell, PeripheralStaining and LabelingBiomarkers, TumorKi-1 AntigenCD30immunohistochemistryperipheral T‐cell lymphomastandardization

Identifiers

PMID39171823
PMCPMC11551810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.